Employer coalition HTA found lower disease complexity predicted better results, while some diabetes patients gained weight. Employers may use it to set coverage rules.
Recap by typeshit. Full story at Insurance Business.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The study will scan the brains of about 180 people as they make food and money choices, looking for changes in how the reward system handles instant gratification.
A law firm looks at how a temporary FDA enforcement pause on peptide compounding could affect pharmacies.
Loading…